Market open· · SEK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Despite a flat quarter and a SEK 20 million inventory write-down, EQL Pharma AB (FRA:7JK) reaffirms its full-year guidance, citing improved stock availability and a robust pipeline.
Despite a challenging quarter with supply chain disruptions, EQL Pharma AB (OSTO:EQL) focuses on strategic launches and market expansions to drive future growth.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.